Mumps virus envelope glycoprotein (F; HN)

The mumps virus envelope glycoproteins comprise two major proteins, fusion protein (F) and hemagglutinin-neuraminidase protein (HN), which protrude from the viral lipid envelope and are essential for infection. The F protein enables the fusion of viral and host cell membranes, facilitating viral entry. The HN protein binds sialic acid-containing receptors on host cells, mediates hemagglutination, and possesses neuraminidase activity important for viral entry and propagation. Both proteins are major targets for neutralizing antibodies, underlie the effectiveness of current mumps vaccines, and are structurally conserved across mumps virus strains, though antigenic variation may exist between genotypes. These glycoproteins are classified as viral receptor-binding (HN) and viral fusion (F) proteins, and are critical determinants of mumps virus infectivity, host specificity, and immunogenicity. While generically referred to as 'Mumps virus envelope glycoprotein', this term is ambiguous as it refers to these two distinct proteins with different functions and properties. For structured queries, specific identification as either F or HN is recommended.

Other names

Fusion glycoproteinF proteinHN glycoproteinHemagglutinin-neuraminidaseHN protein

Vaccines induce production of neutralizing antibodies targeting antigenic sites on F and HN, thereby blocking attachment or fusion and preventing infection. Theoretical neuraminidase inhibitors would inhibit HN enzyme activity and block viral release or spread. Theoretical fusion inhibitors would prevent conformational changes required for membrane fusion by targeting the F protein.